About US
Contact us
-
Carvykti's massive myeloma win; BeiGene's PD-1 comebackJohnson & Johnson and Legend Biotech's Carvykti showed a massive cancer progression benefit in leaked multiple myeloma trial data. The pair also recruited Novartis to help ramp up supply of the C2023/4/21
-
Johnson & Johnson talc cases put on hold—again—by US bankruptcy courtApplying lessons learned from its first failed bankruptcy for talc lawsuits may produce dividends for Johnson & Johnson. Thursday, U.S. bankruptcy judge Michael Kaplanfrozemore than 32023/4/21
-
BeiGene, Novartis' tislelizumab stages comeback with broader stomach cancer trial winWhen BeiGene and Novartis announced a partial trial win for tislelizumab in stomach cancer, doubts started to circulate around the PD-1 inhibitor’s potential. Now, the partners have come back with br2023/4/19
-
Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028Amgenhas scored a win in its bid to defend its key immunology drug Otezla. The U.S. Court of Appeals for the Federal Circuit backed a 2021rulingagainst Novartis' Sandoz and Zydus. That pr2023/4/19
-
Teva wraps up sale of India manufacturing facility to MarksansTeva Pharmaceutical Industriescompleted the sale(PDF) of its manufacturing facility in Goa, India, to Marksans Pharma for an undisclosed price. First revealedin October, the deal wrapped2023/4/17
-
What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her takeNot one, not two, but three of the industry's top diabetes players last month slashed prices on their competing insulins. After Eli Lilly's cut, the strategy was quickly followed by Novo Nordisk and2023/4/17
-
With hard-fought Polivy approval, Roche looks to shake up decades of established practice in lymphomaAfter a regulatory scare, Roche can now kick off work on changing nearly 20 years of clinical practice for the treatment of diffuse large B-cell lymphoma (DLBCL). The FDA has signed off o2023/4/14
-
Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats upA series of acquisitions by GSK, Merck & Co. and Sanofi has analysts at RBC Capital Markets optimistic about the biopharma M&A landscape. And the team has some potential targets in mind.2023/4/14
-
Pfizer moves on up to the West Side, establishing new nerve center at Hudson Yards' Spiral skyscraperFrom medication to meditation, Pfizer’s new West Side Manhattan headquarters is a ritzy real-estate ode to its workers. For more than sixty years, Pfizer has operated out of a revamped re2023/4/12
-
Phathom says it has Voquezna back on track after nitrosamine-related delayA meeting with the FDA has paved the way for Phathom Pharmaceuticals to resubmit its applications for its erosive esophagitis and Helicobacter pylori drug Voquezna, the companysaidon Tuesday.2023/4/12